Canada markets open in 1 hour 1 minute

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
1.7300-0.0400 (-2.26%)
At close: 04:00PM EDT
1.7200 -0.01 (-0.58%)
Pre-Market: 08:26AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.7700
Open1.7700
Bid1.7000 x 40000
Ask0.0000 x 46000
Day's Range1.7100 - 1.7850
52 Week Range1.1200 - 3.5200
Volume11,626,735
Avg. Volume21,207,433
Market Cap3.631B
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Cronos Group Reports 2022 Fourth Quarter and Full-Year Results

    Consolidated net revenue increased 23% in Full Year 2022 compared to Full Year 2021; on a constant currency basis consolidated net revenue increased 28% in Full Year 2022 compared to Full Year 2021 Net revenue in Israel increased 128% in Full Year 2022 compared to Full Year 2021; on a constant currency basis net revenue in Israel increased 137% in Full Year 2022 compared to Full Year 2021 Ended 2022 with $878 million in cash and short-term investments Spinach® became the number one edible brand

  • GlobeNewswire

    Ginkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants

    The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airportsBOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention’s (CDC’s) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV